Polyphenolic Profiling of Green Waste Determined by UPLC-HDMSE
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Trifolium Pratense Extract Induces Apoptosis and Decreases Nitric Oxide Secretion in Human Umbilical Vein Endothelial Cell
WCRJ 2020; 7: e1508 TRIFOLIUM PRATENSE EXTRACT INDUCES APOPTOSIS AND DECREASES NITRIC OXIDE SECRETION IN HUMAN UMBILICAL VEIN ENDOTHELIAL CELL F. KHAZAEI1, M.H. FARZAEI2, S. KHAZAYEL3, M. KHAZAEI2 1Student Research Committee, Kermanshah University of Medical Sciences, Kermanshah, Iran 2Pharmaceutical Sciences Research Center, Kermanshah University of Medical Sciences, Kermanshah, Iran 3Fertility and Infertility Research Center, Health Technology Institute, Kermanshah University of Medical Sciences, Kermanshah, Iran Abstract – Objective: Angiogenesis plays a critical role in tumor growth and metastasis. En- dothelial cell proliferation has been used as an in vitro model of angiogenesis. Trifolium pratense was suggested for cancer treatment in traditional medicine and scientific report. The present study was designed to investigate the effect of T. pratense hydroalcoholic extract on the human umbilical vein endothelial cell (HUVEC) apoptosis and nitric oxide (NO) secretion in vitro. Materials and Methods: Hydroalcoholic extract of T. pratense was prepared and its different concentrations (0, 12.5, 25, 50, 100, 200, 400, 800 μg/ml) were used for cell treatment. Cell viability was assessed by trypan blue, MTT and lactate dehydrogenase methods. Furthermore, nitric oxide (NO) secretion of the cells was measured by Griess reaction, and their apoptosis was evaluated by fluorescent dyes staining. One-way ANOVA was used for data analysis. Results: After 24, 48 and 72 hours treatments, the IC50 values were 1069.35, 174.70 and 68.07 μg/ml, respectively. T. pratense extracts exerted a significant difference between the groups treated compared to the control group (p<0.05) and increasing the dose significantly decreased cell via- bility. T. pratense extract significantly increased LDH in dose- and time-dependent manners in the cell culture medium (p<0.05). -
Antiproliferative Effects of Isoflavones on Human Cancer Cell Lines Established from the Gastrointestinal Tract 1
[CANCER RESEARCH 53, 5815-5821, December 1, 1993] Antiproliferative Effects of Isoflavones on Human Cancer Cell Lines Established from the Gastrointestinal Tract 1 Kazuyoshi Yanagihara, 2 Akihiro Ito, Tetsuya Toge, and Michitaka Numoto Department of Pathology [K. Y, M. N.], Cancer Research [A. L], and Surgery iT. T.], Research Institute for Nuclear Medicine and Biology, Hiroshima University, Kasumi 1-2-3, Minami-ku, Hiroshima 734, Japan ABSTRACT MATERIALS AND METHODS Seven isoflavones, biochanin A, daidzein, genistein, genistin, prunectin, Establishment of Cancer Cell Lines. Tumor tissues were trimmed of fat puerarin, and pseudobaptigenin were tested for cytostatic and cytotoxic and necrotic portions and minced with scalpels. The tissue pieces were trans- effects on 10 newly established cancer cell lines of the human gastrointes- ferred, together with medium, at 10 to 15 fragments/dish to 60-mm culture tinal origin. Proliferation of HSC-41E6, HSC-45M2, and SH101-P4 stom- dishes (Falcon, Lincoln Park, N J). The patient's ascitic tumor cells were ach cancer cell lines was strongly inhibited by biochanin A and genistein, harvested by centrifugation (1000 rpm for 10 min) and plated into 60-mm whereas other stomach, esophageal, and colon cancer lines were moder- dishes. Culture dishes initially selectively trypsinized [trypsin, 0.05% (w/v); ately suppressed by both compounds. Biochanin A and genistein were EDTA, 0.02% (w/v)], to remove overgrowing fibroblasts. In addition, we cytostatic at low concentrations (<20 pg/ml for biochanin A, <10/tg/ml for attempted to remove the fibroblasts mechanically and to transfer the tumor genistein) and were cytotoxic at higher concentrations (>40 pg/ml for cells selectively. -
Light and Temperature Conditions Affect Bioflavonoid Accumulation In
Plant Cell Tiss Organ Cult DOI 10.1007/s11240-014-0502-8 RESEARCH NOTE Light and temperature conditions affect bioflavonoid accumulation in callus cultures of Cyclopia subternata Vogel (honeybush) Adam Kokotkiewicz • Adam Bucinski • Maria Luczkiewicz Received: 20 March 2014 / Accepted: 26 April 2014 Ó The Author(s) 2014. This article is published with open access at Springerlink.com Abstract Callus cultures of the endemic South-African maintained at 24 °C. On the contrary, elevated temperature legume Cyclopia subternata were cultivated under varying (29 °C) applied during the second half of the culture period light and temperature conditions to determine their influ- resulted in over 300 and 500 % increase in CG and PG ence on biomass growth and bioflavonoids accumulation. content (61.76 and 58.89 mg 100 g-1, respectively) while Experimental modifications of light included complete maintaining relatively high biomass yield. darkness, light of different spectral quality (white, red, blue and yellow) and ultraviolet C (UVC) irradiation. The calli Keywords Hesperidin Á In vitro cultures Á Isoflavones Á were also subjected to elevated temperature or cold stress. Light spectral quality Á Temperature regime Á UVC Among the tested light regimes, cultivation under blue irradiation light resulted in the highest levels of hesperidin (H)— 118.00 mg 100 g-1 dry weight (DW) on 28 days of Abbreviations experiment, as well as isoflavones: 7-O-b-glucosides of CG Calycosin 7-O-b-glucoside calycosin (CG), pseudobaptigenin (PG) and formononetin 4-CPPU N-(2-chloro-4-pyridyl)-N0-phenylurea (FG)—28.74, 19.26 and 10.32 mg 100 g-1 DW, respec- (forchlorfenuron) tively, in 14-days old calli. -
Isolation, Identification and Characterization of Allelochemicals/Natural Products
Isolation, Identification and Characterization of Allelochemicals/Natural Products Isolation, Identification and Characterization of Allelochemicals/Natural Products Editors DIEGO A. SAMPIETRO Instituto de Estudios Vegetales “Dr. A. R. Sampietro” Universidad Nacional de Tucumán, Tucumán Argentina CESAR A. N. CATALAN Instituto de Química Orgánica Universidad Nacional de Tucumán, Tucumán Argentina MARTA A. VATTUONE Instituto de Estudios Vegetales “Dr. A. R. Sampietro” Universidad Nacional de Tucumán, Tucumán Argentina Series Editor S. S. NARWAL Haryana Agricultural University Hisar, India Science Publishers Enfield (NH) Jersey Plymouth Science Publishers www.scipub.net 234 May Street Post Office Box 699 Enfield, New Hampshire 03748 United States of America General enquiries : [email protected] Editorial enquiries : [email protected] Sales enquiries : [email protected] Published by Science Publishers, Enfield, NH, USA An imprint of Edenbridge Ltd., British Channel Islands Printed in India © 2009 reserved ISBN: 978-1-57808-577-4 Library of Congress Cataloging-in-Publication Data Isolation, identification and characterization of allelo- chemicals/natural products/editors, Diego A. Sampietro, Cesar A. N. Catalan, Marta A. Vattuone. p. cm. Includes bibliographical references and index. ISBN 978-1-57808-577-4 (hardcover) 1. Allelochemicals. 2. Natural products. I. Sampietro, Diego A. II. Catalan, Cesar A. N. III. Vattuone, Marta A. QK898.A43I86 2009 571.9’2--dc22 2008048397 All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying or otherwise, without the prior permission of the publisher, in writing. The exception to this is when a reasonable part of the text is quoted for purpose of book review, abstracting etc. -
IN SILICO ANALYSIS of FUNCTIONAL Snps of ALOX12 GENE and IDENTIFICATION of PHARMACOLOGICALLY SIGNIFICANT FLAVONOIDS AS
Tulasidharan Suja Saranya et al. Int. Res. J. Pharm. 2014, 5 (6) INTERNATIONAL RESEARCH JOURNAL OF PHARMACY www.irjponline.com ISSN 2230 – 8407 Research Article IN SILICO ANALYSIS OF FUNCTIONAL SNPs OF ALOX12 GENE AND IDENTIFICATION OF PHARMACOLOGICALLY SIGNIFICANT FLAVONOIDS AS LIPOXYGENASE INHIBITORS Tulasidharan Suja Saranya, K.S. Silvipriya, Manakadan Asha Asokan* Department of Pharmaceutical Chemistry, Amrita School of Pharmacy, Amrita Viswa Vidyapeetham University, AIMS Health Sciences Campus, Kochi, Kerala, India *Corresponding Author Email: [email protected] Article Received on: 20/04/14 Revised on: 08/05/14 Approved for publication: 22/06/14 DOI: 10.7897/2230-8407.0506103 ABSTRACT Cancer is a disease affecting any part of the body and in comparison with normal cells there is an elevated level of lipoxygenase enzyme in different cancer cells. Thus generation of lipoxygenase enzyme inhibitors have suggested being valuable. Individual variation was identified by the functional effects of Single Nucleotide Polymorphisms (SNPs). 696 SNPs were identified from the ALOX12 gene, out of which 73 were in the coding non-synonymous region, from which 8 were found to be damaging. In silico analysis was performed to determine naturally occurring flavonoids such as isoflavones having the basic 3- phenylchromen-4-one skeleton for the pharmacological activity, like Genistein, Diadzein, Irilone, Orobol and Pseudobaptigenin. O-methylated isoflavones such as Biochanin, Calycosin, Formononetin, Glycitein, Irigenin, 5-O-Methylgenistein, Pratensein, Prunetin, ψ-Tectorigenin, Retusin and Tectorigenine were also used for the study. Other natural products like Aesculetin, a coumarin derivative; flavones such as ajoene and baicalein were also used for the comparative study of these natural compounds along with acteoside and nordihydroguaiaretic acid (antioxidants) and active inhibitors like Diethylcarbamazine, Zileuton and Azelastine as standard for the computational analysis. -
Phenolic Constituents of Trifolium Resupinatum Var. Minus: Protection Against Rosiglitazone Induced Osteoporosis in Type 2 Diabetic Male Rats
Journal of Applied Pharmaceutical Science Vol. 7 (05), pp. 174-183, May, 2017 Available online at http://www.japsonline.com DOI: 10.7324/JAPS.2017.70530 ISSN 2231-3354 Phenolic constituents of Trifolium resupinatum var. minus: Protection against rosiglitazone induced osteoporosis in type 2 diabetic male rats Mona E. S. Kassem1*, Mona M. Marzouk1, Amani A. Mostafa2, Wagdy K. B. Khalil3, Hoda F. Booles3 1Department of Phytochemistry and Plant Systematics, National Research Centre, 33 El Bohouth St., Dokki, Giza, Egypt. 2Department of Ceramics, Laboratory of Nanomedicine and Tissue Engineering, National Research Centre, 33 El Bohouth St., Dokki, Giza, Egypt. 3Department of Cell Biology, National Research Centre, 33 El Bohouth St., Dokki, Giza, Egypt. ABSTRACT ARTICLE INFO Article history: Thiazolidinediones, an antidiabetic drug, promote bone loss and provoke fractures, suggesting a protective role Received on: 26/12/2016 of phytoestrogens rich herbal supplement along with rosiglitazone. The aqueous methanol extract (AME) of Accepted on: 09/03/2017 Trifolium resupinatum L. var. minus Boiss. (Fabaceae) and defatted AME (DAME) protective effects were Available online: 30/05/2017 assessed against rosiglitazone (Ros) inducing osteoporosis in type 2 diabetic male rats. Eighty male Albino rats (10/group) were used. OPG, RANKL and β2- microglobulin serum levels, femur BMD (Dexa) and OC, COL Key words: and ACP5 osteogenic genes mRNA (qRT-PCR) were evaluated in Ros-rats + AME or DAME (24, 12, 6 mg/kg Persian clover, bw/d, each). Ros-rats + DAME (24 mg/kgbw) revealed the most significant effects on bone biomarkers. It Thiazolidinediones, diabetes, modulated OPG (ng mL-1), RANKL (pg mL-1) and β2- microglobulin (μg mL-1) serum levels. -
Ep 3138585 A1
(19) TZZ¥_¥_T (11) EP 3 138 585 A1 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) Int Cl.: 08.03.2017 Bulletin 2017/10 A61L 27/20 (2006.01) A61L 27/54 (2006.01) A61L 27/52 (2006.01) (21) Application number: 16191450.2 (22) Date of filing: 13.01.2011 (84) Designated Contracting States: (72) Inventors: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB • Gousse, Cecile GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO 74230 Dingy Saint Clair (FR) PL PT RO RS SE SI SK SM TR • Lebreton, Pierre Designated Extension States: 74000 Annecy (FR) BA ME •Prost,Nicloas 69440 Mornant (FR) (30) Priority: 13.01.2010 US 687048 26.02.2010 US 714377 (74) Representative: Hoffmann Eitle 30.11.2010 US 956542 Patent- und Rechtsanwälte PartmbB Arabellastraße 30 (62) Document number(s) of the earlier application(s) in 81925 München (DE) accordance with Art. 76 EPC: 15178823.9 / 2 959 923 Remarks: 11709184.3 / 2 523 701 This application was filed on 29-09-2016 as a divisional application to the application mentioned (71) Applicant: Allergan Industrie, SAS under INID code 62. 74370 Pringy (FR) (54) STABLE HYDROGEL COMPOSITIONS INCLUDING ADDITIVES (57) The present specification generally relates to hydrogel compositions and methods of treating a soft tissue condition using such hydrogel compositions. EP 3 138 585 A1 Printed by Jouve, 75001 PARIS (FR) EP 3 138 585 A1 Description CROSS REFERENCE 5 [0001] This patent application is a continuation-in-part of U.S. -
Isoflavonoid Biosynthesis 21321.Pdf
Isoflavonoid Biosynthesis https://www.kegg.jp/kegg-bin/highlight_pathway?scale=1.0&map=map00943&keyword=flavonoids Isoflavonoids are biologically active compounds, such as phytoestrogens, produced by pea family plants. While flavonoids (in the narrow sense) have the 2- phenylchromen-4-one backbone, isoflavonoids have the 3-phenylchromen-4-one backbone with no hydroxyl group substitution at position 2. Isoflavonoids are derived from the flavonoid biosynthesis pathway via liquiritigenin or naringenin. (Flavonoid Biosynthesis) -> [1,2] 1) Liquiritigenin -> [1,2,3] 1) flavone synthesis I & II -> 7,4’Dihydroxyflavone OR 2) flavonoid 6-hydroxylase -> 6,7,4’-Trihydroxyflavanone -> 2- hydroxyisoflavone synthase -> 2,6,7,4’-tetrahydroxyisoflavanone -> 6- Hydroxydaidzein -> Glycitein -> isoflavone 7-O-glucosyltransferase -> Glycitein 7-O-glucoside -> isoflavone 7-O-glucoside-6’’-O-malonyltransferase -> Glycitein 7-O-glucoside-6”-O-malonate OR 3) 2-hydroxyisoflavanone synthase -> 2,7,4’Trihydroxyisoflavanone -> [1,2] 1) Feedback Loop 2,7,4’-trihydroxyisoflavanone 4’-O-methyltransferase / isoflavone 4’-O-methyltransferase -> 2,7-Dihydroxy-4’-methoxyisoflavanone -> 2- hydroxyisoflavanone dehydratase -> Formononetin OR 2) 2-hydroxyisoflavone dehydratase -> Daidzein -> [1,2,3,4,5] 1) isoflavone/4’-methoxyisoflavone 2’-hydroxylase -> 2’Hydroxydaidzein -> 2’Hydroxydaidzein reductase -> 2’-Hydroxydihydrodaidzein -> 3,9-Dihydroxypterocarpan -> 3,9-dihydroxypterocarpan 6a-monooxygenase -> 3,6,9- Trihydroxypterocarpan -> [1,2] 1) trihydroxypterocarpan dimethylallyltransferase -
PDF-Document
Supplementary Materials 1 Metabolomics profiling analysis of red clover Table S1. Compound identification of red clover in positive and negative ion modes. MS1 No RT Ion Ion Measur Predicte Ste Le Flow Err MS2 MS3 Identification . min Form Formula ed d m af er ppm m/z m/z [M − 195.050 1 1.43 C6H11O7 195.0499 2.82 Gluconic acid ++ ++ +++ H]- 5 179.03506(C9H7O4); Benzoylcitronensa [M − 295.045 295.0448 ++ 2 4.46 C13H11O8 0.67 133.01451(C4H5O5); [295-179]135.04524(C8H7O2); ure ++ +++ H]- 0 4 + 115.00400(C4H3O4); [M + 355.102 ++ 3 5.42 C16H19O9 355.1024 1.21 chlorogenic acid + +++ H]+ 8 + [433-271]253.04956(C15H9O4); 243.06529(C14H11O4); [M + 433.111 Genistein- ++ 4 6.60 C21H21O10 433.1129 −3.54 271.06067(C15H11O5); 215.07042(C13H11O3); +++ +++ H]+ 4 glucoside + 153.01839(C7H5O4); 149.02335(C8H5O3); [M + 417.117 5 6.71 C21H21O9 417.1180 −2.34 239.07021(C15H11O3) daidzin + ++ +++ H]+ 0 [M + 447.127 calycosin-7-O-β-D- ++ 6 7.20 C22H23O10 447.1286 −1.91 269.08072(C16H13O4) +++ +++ H]+ 7 glucoside + 1 [533-285]270.05258(C15H10O5); Calycosin-7-O-β- [M + 533.127 253.04982(C15H9O4); ++ 7 8.03 C25H25O13 533.1290 −3.54 285.07642(C16H13O5); D-glucoside 4′′-O- +++ +++ H]+ 1 225.05478(C14H9O3); + malonate 137.02333(C7H5O3); [M + 433.112 ++ 8 8.95 C21H21O10 433.1129 −2.11 255.06516(C15H11O4) genistin ++ +++ H]+ 0 + [519-271]253.04958(C15H9O4,); Genistein- 243.06526(C14H11O4); [M + 519.111 433.11377(C21H21O10); glucoside ++ 9 9.31 C24H23O13 519.1133 −3.25 215.07045(C13H11O3); - +++ H]+ 6 271.06073(C15H11O5); malonate + 153.01833(C7H5O4); 149.02333(C8H5O3); -
Botanicals: a Phytocosmetic Desk Reference
BOTANICALS: A PHYTOCOSMETIC DESK REFERENCE Frank S. D’Amelio, Sr. CRC Press Boca Raton New York i © 1999 by CRC Press LLC Acquiring Editor: Norina Frabotta Project Editor: Susan Fox Marketing Manager: Becky McEldowney Cover design: Violet Liquori Library of Congress Cataloging-in-Publication Data Catalog record is available from the Library of Congress. This book contains information obtained from authentic and highly regarded sources. Reprinted material is quoted with permission, and sources are indicated. A wide variety of references are listed. Reasonable efforts have been made to publish reliable data and information, but the author and the publisher cannot assume responsibility for the validity of all materials or for the consequences of their use. Neither this book nor any part may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopying, microfilming, and recording, or by any information storage or retrieval system, without prior permission in writing from the publisher. The consent of CRC Press LLC does not extend to copying for general distribution, for promotion, for creating new works, or for resale. Specific permission must be obtained in writing from CRC Press LLC for such copying. Direct all inquiries to CRC Press LLC, 2000 Corporate Blvd., N.W., Boca Raton, Florida 33431. Trademark Notice: Product or corporate names may be trademarks or registered trademarks, and are only used for identification and explanation, without intent to infringe. © 1999 by CRC Press LLC No claim -
( 12 ) United States Patent
US010722444B2 (12 ) United States Patent ( 10 ) Patent No.: US 10,722,444 B2 Gousse et al. (45 ) Date of Patent : Jul. 28 , 2020 (54 ) STABLE HYDROGEL COMPOSITIONS 4,605,691 A 8/1986 Balazs et al . 4,636,524 A 1/1987 Balazs et al . INCLUDING ADDITIVES 4,642,117 A 2/1987 Nguyen et al. 4,657,553 A 4/1987 Taylor (71 ) Applicant: Allergan Industrie , SAS , Pringy (FR ) 4,713,448 A 12/1987 Balazs et al . 4,716,154 A 12/1987 Malson et al. ( 72 ) 4,772,419 A 9/1988 Malson et al. Inventors: Cécile Gousse , Dingy St. Clair ( FR ) ; 4,803,075 A 2/1989 Wallace et al . Sébastien Pierre, Annecy ( FR ) ; Pierre 4,886,787 A 12/1989 De Belder et al . F. Lebreton , Annecy ( FR ) 4,896,787 A 1/1990 Delamour et al. 5,009,013 A 4/1991 Wiklund ( 73 ) Assignee : Allergan Industrie , SAS , Pringy (FR ) 5,087,446 A 2/1992 Suzuki et al. 5,091,171 A 2/1992 Yu et al. 5,143,724 A 9/1992 Leshchiner ( * ) Notice : Subject to any disclaimer , the term of this 5,246,698 A 9/1993 Leshchiner et al . patent is extended or adjusted under 35 5,314,874 A 5/1994 Miyata et al . U.S.C. 154 (b ) by 0 days. 5,328,955 A 7/1994 Rhee et al . 5,356,883 A 10/1994 Kuo et al . (21 ) Appl . No.: 15 /514,329 5,399,351 A 3/1995 Leshchiner et al . 5,428,024 A 6/1995 Chu et al . -
(12) Patent Application Publication (10) Pub. No.: US 2012/0208890 A1 Gousse Et Al
US 20120208890A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2012/0208890 A1 Gousse et al. (43) Pub. Date: Aug. 16, 2012 (54) STABLE HYDROGEL COMPOSITIONS of application No. 127956,542, filed on Nov.30, 2010, INCLUDING ADDITIVES which is a continuation-in-part of application No. 12/714,377, filed on Feb.26, 2010, which is a continu (75) Inventors: Cecile Gousse, Dingy Saint Clair ation-in-part of application No. 12/687,048, filed on (FR); Pierre F. Lebreton, Annecy Jan. 13, 2010. (FR); Nicolas Prost, Mornant (FR): Sumit Paliwal, Goleta, CA (US); Publication Classification Dennis Van Epps, Goleta, CA (US) (51) Int. C. (73) Assignee: ALLERGAN, INC. Irvine, CA A6IR 8/4I (2006.01) (US) A61O 19/08 (2006.01) A6IR 8/42 (2006.01) (21) Appl. No.: 13/350,518 (52) U.S. Cl. ......................................... 514/626; 514/653 (22) Filed: Jan. 13, 2012 (57) ABSTRACT Related U.S. Application Data The present specification generally relates to hydrogel com (63) Continuation-in-part of application No. 13/005,860, positions and methods of treating a soft tissue condition using filed on Jan. 13, 2011, which is a continuation-in-part Such hydrogel compositions. Patent Application Publication Aug. 16, 2012 Sheet 1 of 7 US 2012/0208890 A1 lication Publication ug. 16, 2012 Sheet 2 of 7 co & S. N SESo 9 CD s Y NI C O O CN ve ve D an an 5 S. 5 3. 9. S. Patent Application Publication Aug. 16, 2012 Sheet 3 of 7 US 2012/0208890 A1 00Z?000).00800900700Z0 O.GZ?eSÅep~ Patent Application Publication Aug.